ifosfamide / Generic mfg. - LARVOL DELTA

Malignant peripheral nerve sheath tumors: a report from children's oncology group study ARST0332. (PubMed, J Natl Cancer Inst) - P3 | "The treatment strategy in ARST0332 achieved excellent outcomes for low-risk MPNST. Patients with high risk (metastatic) MPNST have poor outcomes and novel treatments are needed. (NCT00346164)."

Journal • Brain Cancer • Genetic Disorders • Neurofibromatosis • Neurofibrosarcoma • Oncology • Sarcoma • Solid Tumor

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status (ASH 2025) - "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) is a common regimen that is well-tolerated in older adults with other comorbidities, for whom treatment of DLBCL is challenging and has inferior outcomes...The most common 2L treatment regimens were rituximab, ifosfamide, carboplatin, plus etoposide in ASCT (n=41, 62.1%) and bendamustine plus rituximab (n=62, 18.6%) in non-ASCT treated groups...A higher percentage of patients in the non-ASCT treated group, specifically in the R-GemOx subgroup, were older with higher ECOG scores and inferior treatment related outcomes, including a minority alive at 2 years. These findings highlight a continuing unmet need for more effective, safer treatments for patients with R/R DLBCL ineligible for or unable to access ASCT or CAR-T."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy (ASH 2025) - " 23 pts were referred to holding: 6 partial-brain irradiation, 4 intrathecal CHT, 2 polatuzumab vedotin, 5 ibrutinib, 1 HD-ifosfamide-based CHT, 2 MATRix regimen, 1 thiotepa-based ASCT, combinations of these strategies in 2...Only one pt experienced G3-4 CRS, all CRS cases were successfully treated with tocilizumab and steroids, anakinra was used in 2 cases... Varied presentation and high aggressivity of SCNSL impede the use of a uniform treatment for these pts. SCNSL refractory to HDMTX-based polyCHT can benefit significantly from a tailored multimodal holding based on the pt's history and extension of disease. Only pts with good PS and responsive to holding therapy should be offered CAR-T to avoid superfluous toxicity."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Epilepsy • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study (ASH 2025) - "Polatuzumab vedotin (Pola), an antibody-drug conjugate targeting CD79b, has demonstrated safety and efficacy when combined with bendamustine and rituximab in transplant-ineligible patients (pts) with relapsed DLBCL pts. We evaluated the safety and efficacy of Pola-ICE regimen—comprising polatuzumab vedotin, ifosfamide, carboplatin, and etoposide—with or without the addition of rituximab in R/R DLBCL pts in the real world...All patients received Pola-ICE: Pola 1.8 mg/kg (day 1), ifosfamide 4000 mg/m² (administered in two divided doses, days 1–2, with MESNA infusion), carboplatin AUC 4 (day 2), etoposide 100 mg/m² (days 1–3), repeated every 21 days up to 6 cycles... Pola-ICE, with or without rituximab, demonstrated promising efficacy with high-quality responses and manageable toxicity in heavily pretreated R/R DLBCL pts. This salvage regimen may serve as a viable option for high-risk patients, potentially enabling subsequent curative-intent therapies."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD79B

Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma (ASH 2025) - "All-line therapies were backbone-classified as: C-AC: anthracycline combinations C-SALV: cytarabine/platinum/ifosfamide salvage AV/IM: antiviral-immunomodulatory TT/IT: targeted/immuno-trial agents ALL stratum denoting the entire cohort across backbones Responses were defined as Complete/Partial Remission (CR/PR), Stable Disease (SD), Progression of Disease (PD), and Death, collected from manual chart review. Regimen-stratified genomics in ATLL nominates DIS3, PDGFRB, DNMT3A, ARID1B as genes associated with benefit and IRF4, CARD11, CIC, ATG2B, and ATM as mutations associated with resistance; ARID1B is context-dependent under C-AC; PDGFRB+DNMT3A is associated with incremental benefit. These findings support that exploration of NGS-guided treatment strategies may enable more personalized, regimen-optimized care in ATLL."

Clinical • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • ARID1B • ATG2B • ATM • BRCA1 • CARD11 • DNMT3A • IRF4 • NUP98 • PDGFRB • PLCG1 • PTPRC • TNFAIP3

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma (ASH 2025) - P1 | "With universal prior rituximab exposure in pts withR/R LBCL, salvage strategies may be improved by incorporating novel agents instead of rituximabretreatment...All pts receive at least 2 cyclesof concurrent Mosun + platinum-based chemotherapy, with chemotherapy per treating physician (Arm A:dexamethasone, cytarabine, oxaliplatin [DHAX]; Arm B: ifosfamide, carboplatin, etoposide [ICE])...Pts receive 20mg IV dexamethasone prior to each C1-C2Mosun dose, with optional steroid premeds thereafter...Nine pts experienced CRS (all gr1; no tocilizumab required)... Mosun + DHAX/ICE demonstrated a manageable safety profile with low-grade CRS.Preliminary efficacy results reveal promising anti-lymphoma activity in a high-risk population, with highCR rate and no progressions after CR with relatively short follow-up. This regimen is encouraging forfurther study. Long-term efficacy data are awaited to better assess remission durability."

Clinical • B Cell Lymphoma • Cardiovascular • CNS Disorders • CNS Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Psychiatry • Septic Shock • Thrombocytopenia • Thrombosis • CD20

primary thromboprophylaxis using direct oral anti-coagulants (DOAC) in malignant pediatric tumors with vascular compression (ASH 2025) - "Sarangi previously demonstrated a reduction inthrombotic events for patients with mediastinal masses and tumor-related vascular compression (TRVC)who received prophylactic enoxaparin (Sarangi et...Fourteen patients (≥12 years and >40 kg) receivedapixaban (2.5 mg twice a day) and 5 patients received rivaroxaban (weight-based dosing)...On apixaban, 1 patient had rapid self-resolution of epistaxis, and another had hematuria withconcurrent ifosfamide administration...Though limited by its mostly retrospective design, small sample size, and single-institution population,our study highlights an at-risk subgroup of pediatric oncology patients with TRVC that may benefit fromuniversal primary thromboprophylaxis with a DOAC. Larger studies are needed to evaluate this further."

Clinical • Desmoid Tumors • Fibrosis • Hematological Malignancies • Lymphoma • Neuroblastoma • Obesity • Oncology • Pediatrics • Sarcoma • Solid Tumor • Venous Thromboembolism

Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma (ASH 2025) - "Mitoxantrone Hydrochloride Liposome (Lipo-MIT), aliposomal anthracycline with enhanced accessibility to mass tumor, has shown promising clinical efficacyin hematological malignancies. Here, we evaluated the efficacy and safety of R/G/Z-MINE regimenincluding CD20 antibody, Lipo-MIT, ifosfamide and etoposide as BT prior to CAR-T in patients (pts) withaggressive, bulky, or rapidly progressive R/R B-cell lymphoma.We retrospectively enrolled pts with R/R B-cell lymphoma who received at least one cycle of R/G/Z-MINEregimen before CAR-T administration in a single institution from Feb 2022 to Aug 2024. Anti-CD20monoclonal antibodies were administered on day 0, including rituximab or zebrituzumab at 375 mg/m²or obinutuzumab at 1000 mg...In this pragmatic clinical study conducted in a cohort of pts with high tumor burden and rapidlyprogressive disease, R/G/Z-MINE regimen was shown to be a feasible bridging strategy that achievedeffective tumor debulking and controllable..."

B Cell Lymphoma • Burkitt Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma (ASH 2025) - "Grade 4 hematological toxicityoccurred in 2 patients. No patients died of toxicity.ConclusionsThe preliminary results of this study show that chidamide combined with the MIEDD regimen has goodefficacy and safety in the treatment of patients with newly diagnosed primary CNS T-cell lymphoma.Building on these encouraging results, we will conduct a Phase II clinical trial, in which the cerebrospinalfluid permeability of chidamide and its optimal dosage will be the key focus."

Clinical • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Primary Central Nervous System Lymphoma • T Cell Non-Hodgkin Lymphoma

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma (ASH 2025) - P2 | "Moreover,severe short- and long-term side effects remain major concerns.Recent studies suggest high response rates of up to 95% and unprecedented progression-free survival(PFS) with anti-programmed cell death protein 1 (PD-1)-based salvage regimens such as pembrolizumab,gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD)...Initiatedin March 2024 at four German centers, the trial has enrolled 23 patients to date.Patients receive an initial cycle of pembrolizumab followed by two cycles of P-ICE (pembrolizumab,ifosfamide, carboplatin, etoposide). After PET restaging, complete responders continue with two morecycles of P-ICE, while patients failing to achieve a complete response switch to two cycles of P-DHAP(pembrolizumab, dexamethasone, high-dose cytarabine, cisplatin)...The interim analysis of the Pembro-CORE trial demonstrates promising early results for a PET-adapted,HD-CT-free treatment strategy in first-relapsed cHL. A high CMR of 93.3% was observed among..."

P2 data • Acute Kidney Injury • Classical Hodgkin Lymphoma • Dermatitis • Dermatology • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Renal Disease • Respiratory Diseases

Immune checkpoint Inhibitors' impact on outcomes of relapsed and refractory Hodgkin lymphoma: A real-world study (ASH 2025) - "Adults with R/R CHL who received systemic therapy were identified and assigned to one of fivepropensity score–matched comparisons: (1) brentuximab vedotin (BV) plus nivolumab vs BV alone, (2)nivolumab alone vs BV, (3) Ifosfamide, carboplatin and etoposide (ICE) plus nivolumab vs ICE alone, (4)ICE plus pembrolizumab vs ICE alone, and (5) ICE plus nivolumab vs ICE plus pembrolizumab. Toxicity outcomes, including VTE and ICU admission, were low and comparable across treatmentarms. These findings support broader real-world adoption of ICI-based regimens and warrant prospectivevalidation."

Checkpoint inhibition • Clinical • Real-world • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Venous Thromboembolism

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion (ASH 2025) - "The combination showed highly promising efficacy with overall response rate of 100.0% and77.8% complete response rate. These results support the ongoing phase II portion of this study."

Combination therapy • P1/2 data • B Cell Lymphoma • CNS Lymphoma • Dermatology • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia

ICE therapy for primary and secondary central nervous system involvement of lymphomas (ASH 2025) - "Due to its CNS-penetrating properties, ifosfamide, carboplatin, and etoposide (ICE) protocol with or without rituximabhas become a frequently used salvage regimen for these lymphomas...Prior methotrexate (MTX) exposure did not appearto influence treatment response. The leading cause of death was disease progression, followed by sepsisand one case of CAR-T associated ICANS.In summary, R-ICE regimen is effective and tolerable in patients with CNS involvement and can serve as abridge to advanced and potentially curative approaches. These findings support the role of R-ICE in CNSlymphoma and highlight areas for further prospective investigation."

CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Septic Shock

Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study (ASH 2025) - "The R-MIAD regimen was planned as: rituximab 375 mg/m² d0, MTX 3.5 g/m² d1 [for those >65 years old,partially discretionary to 3g/m2 depending on the general condition of the patient], ifosfamide (IFO) 1.5g/m² d2, cytarabine (HD-AraC) 2 g/m² d3, dexamethasone (DEX) 10 mg d1-3, every 21 days as 1 cycle.Calcium folinate salvage was started every 6 h for a total of 8 doses after 24 h of MTX administrationevery 6 h for a total of 8 times, while with regular monitoring of the blood MTX concentration of MTX.During ifosfamide administration, 300 mg/m² of mesna was administered simultaneously at time 0, 4hours, and 8 hours for urinary tract protection... Our results suggest that R-MIAD regimen is a feasible, safety-manageable, and effectivecombination therapy for patients with newly diagnosed PCNSL. Prospective clinical trials are still neededfor further verification of R-MIAD regimen in first-line treatment of PCNSL."

Clinical data • Combination therapy • Observational data • Retrospective data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Thrombocytopenia • BCL6 • IRF4 • MME

Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL) (ASH 2025) - "Among 481 patients who initiated 2L from 2018-21 (before 2L CAR T was approved), the largest subset(38.3%, n=184) received rituximab in combination with ifosfamide, carboplatin, etoposide (R-ICE) ordexamethasone, ara-C, and cisplatin (R-DHAP), of whom 20.7% (38/184) subsequently received HSCT.Among 365 patients who initiated 2L from 2022-24, only 41 (11.2%) received R-ICE/DHAP, of whom 7.3%(3/41) subsequently received HSCT. With the emergence of alternative 2L therapies like CAR T, the paradigm of 2L R-ICE/DHAP followed byHSCT may be losing relevance. CAR T therapy is extending treatment-free intervals, a proxy for prolongeddisease control, and is showing promise in extending rwOS over less durable alternatives. These findingsalso reinforce the value of CAR T in improving survival outcomes in 2L and 3L settings and the potentialimpact of bringing CAR T into an upfront setting."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Real-world survival, cognitive and health-related quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma (ASH 2025) - "Background : Outcomes for primary central nervous system lymphoma (PCNSL) have been improved withhigh-dose methotrexate (HD-MTX)/Thiotepa-based chemotherapy followed by autologous stem celltransplantation... This study supports HD-MTX/Ifosfamide as an effective, well-tolerated regimen for younger,fit PCNSL patients. WBRT remains a valuable consolidation therapy to prevent recurrence without apronounced decline in cognitive function compared with other lymphoma survivors. However, PCNSLsurvivors may experience subtle declines in attention, executive function, and HRQoL."

Clinical • HEOR • Real-world • Real-world evidence • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

Adding selinexor to ifosfamide, etoposide and desametasone does not improve the outcome in relapsed and refractory peripheral T-cell lymphomas: First report of phase II S-ide study. (ASH 2025) - P2 | "Introduction: The prognosis of relapsed or refractory (R/R) Peripheral T-cell lymphomas (PTCL) is verypoor, except for CD30+ ALK positive PTCLs patients treated with brentuximab-vedotin andchemotherapy...In a small phase I study, selinexor incombination with high-dose dexamethasone, ifosfamide, carboplatin and etoposide (D-ICE) has shownpromising overall response rate (ORR, 91%) and complete response (CR, 82%) in R/R PTCLs, (Tang et al.Haematologica 2021)... In the pilot phase II study S-IDE, the primary end-point was not met, with ORR of 41% at theend of induction. The addition of selinexor to ifosfamide, etoposide, dexamethasone did not ameliorateprognosis in relapsed/refractory PTCLs, the clinical outcome is similar to standard therapies available inthis setting. Biological analyses are ongoing."

P2 data • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • ALK • CDKN2A • CDKN2B • FAT1 • GATA3 • KDM6A • KMT2A • KMT2B • PRDM1 • STAT3 • TBX21 • TNFRSF8 • TP53 • TP63 • XPO1

Diagnosis and Treatment of Laryngeal Extranodal Natural Killer/T-cell Lymphoma. (PubMed, Cureus) - "The patient received CHOP chemotherapy (cyclophosphamide 700 mg, doxorubicin 50 mg, vincristine 2 mg, dexamethasone 20 mg), which was later changed to DeVIC (dexamethasone 40 mg, etoposide 70 mg, ifosfamide 1,000 mg, carboplatin 200 mg) with local radiotherapy. Due to the inability to place a nasogastric tube, a Witzel gastrostomy was performed. However, the patient died from non-oncological causes."

Journal • Cough • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Laryngeal Cancer • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Squamous Cell Carcinoma • T Cell Non-Hodgkin Lymphoma • Tuberculosis

Neoadjuvant Chemotherapy in Primary Pulmonary Synovial Sarcoma followed by open thoracotomy and right bilobectomy: A case report (ESMO Asia 2025) - "Neoadjuvant chemotherapy with doxorubicin and ifosfamide is an option for localized SS of > 5cm with aggressive features. Multimodality treatment may achieve a favorable outcome in patients."

Case report • Clinical • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • SS18 • SSX1

Adult FOX01-positive Alveolar Rhabdomyosarcoma of the Paranasal Sinus: Rapid Progression Despite Multimodal Therapy - A Case Report (ESMO Asia 2025) - "He received six cycles of VAC/IE (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide) every 21 days with G-CSF support, achieving partial response. Inclusion in international rare sarcoma trials is critical to improve prognosis. Keywords Adult rhabdomyosarcoma, alveolar subtype, FOXO1 fusion, multidisciplinary management, paranasal sinus tumor"

Case report • Clinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor • FOXO1

Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma - a retrospective multicentre clinical study. (PubMed, Haematologica) - "Not available."

Journal • Retrospective data • CNS Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Sinonasal extraosseous Ewing's sarcoma of the nasal cavity with EWSR1: FLI1 fusion - a rare case report from Nepal. (PubMed, Ann Med Surg (Lond)) - "The patient received the first cycle of the chemotherapy regimen of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VAC/IE) and was discharged in a stable condition. This case emphasizes the need to consider EES in the differential diagnosis of nasal masses and highlights the necessity of molecular testing for EWSR1 rearrangements to confirm the diagnosis and guide therapy. Increased awareness and reporting are vital to enhancing diagnosis and management of this rare entity."

Journal • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • CD99 • EWSR1 • FLI1

Pulmonary metastasis from adult-type granulosa cell tumor of the testis: a rare case report and literature review. (PubMed, Curr Med Res Opin) - "Second-line treatment with tislelizumab, nab-paclitaxel, carboplatin, and anlotinib led to temporary stabilization. Salvage chemotherapy with doxorubicin, ifosfamide, and dacarbazine failed, and the patient died two months later...Patients who undergo complete resection of metastatic lesions tend to achieve better outcomes, whereas responses to systemic therapy are generally poor. Early identification of high-risk features and consideration of retroperitoneal lymph node dissection may improve prognosis in selected patients."

Journal • Lung Cancer • Oncology • Testicular Cancer • FOXL2

Relapsed Classical Hodgkin Lymphoma in Pregnancy in Two Patients Managed With a Multidisciplinary Approach. (PubMed, Case Rep Oncol Med) - "The first patient with Stage IIIB cHL achieved a complete response (CR) with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) prior to pregnancy but relapsed at 10 weeks of gestation. After delivery, both patients underwent ICE (ifosfamide, carboplatin, and etoposide), followed by consolidation with autologous hematopoietic cell transplantation (auto-HCT). These cases highlight the balance needed to maintain control of disease to allow a safe and uneventful pregnancy."

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation